Edwards Lifesciences (EW) Receivables - Net (2009 - 2026)

Edwards Lifesciences' Receivables - Net history runs 18 years deep, the most recent figure standing at $775.7 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 15.91% year-over-year to $775.7 million; the TTM figure through Mar 2026 stood at $775.7 million (up 15.91% YoY), while the FY2025 annual figure was $659.6 million, up 2190.28% from the prior year.
• Receivables - Net was $775.7 million for Q1 2026 at Edwards Lifesciences, up from $659.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $817.6 million in Q1 2024 to a low of $28.8 million in Q4 2024.
• Historically, Receivables - Net has averaged $667.8 million across 5 years, with a median of $697.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net tumbled 96.27% in 2024, then soared 2190.28% in 2025.
• A 5-year view of Receivables - Net shows it stood at $643.0 million in 2022, then climbed by 19.98% to $771.5 million in 2023, then sank by 96.27% to $28.8 million in 2024, then jumped by 2190.28% to $659.6 million in 2025, then climbed by 17.6% to $775.7 million in 2026.
• The last three Receivables - Net figures came in at $775.7 million (Q1 2026), $659.6 million (Q4 2025), and $693.3 million (Q3 2025), per Business Quant data.